- Market Leadership. We are a dominant market leader in Taiwan market as measured by market shares, number of customers, sales revenue and field awards by major Taiwanese institutions. With proven experience in the market, our products are widely recognized as featured in major TV channels, news magazine, outdoor space, and web portals etc.
- Technology Leadership. Apart from SOP of sales & marketing, nearly a decade’s experience in Immune-cell therapy aids us make the best decision in procedure design and safety control etc.
- Sales Channel Network. We have established solid partnership with major channel partners, such as major insurance agencies, health centers, medical check-up centers, drug stores, clinics, and other sales point partners in Taiwan market, and we are currently undergoing conversation with major channel partnership across Hong Kong, Macao, and mainland China.
- Solid Partnership. We have built solid partnership built with therapy partners in Japan, Taiwan, China and Macao, such as: i) Japan hospitalst; ii) Taiwan leading institutes and hospitals serving as long-term partners; and iii) China leading hospitals has provided over 100 clinical trials patients to the company.
- Favorable Capital Market Recognition. In Taiwan, bio-tech stocks are highly favored by the market and we are one of the few profitable & high-technology companies amongst the cluster. Our underwriter is Bank SinoPac, who is the most experienced investment bank in bio-tech listing in Taiwan market.
|
